
Hercules Capital, Inc. (NYSE: HTGC) is the leading and largest specialty finance company focused on providing senior secured venture growth loans to high-growth, innovative venture capital-backed companies in technology and life sciences. Founded in December 2003, it has committed over $27 billion to more than 700 companies since inception.
Deal activity decreased year-over-year (3 deals in the last 12 months vs 5 prior). Average disclosed round size is $83.6M (across 122 rounds with reported amounts).
Portfolio
78
Fund Size
—
Top Stage
Unknown
Last 12 Mo
2
Team
Michael Dutra
Managing Director
Roy Y. Liu
Managing Director
Ruslan Sergeyev
Managing Director, Venture Lending
Eddie Lopez
Principal
Scott Bluestein
Chief Executive Officer and Chief Investment Officer
Catherine Jhung
Co-lead Technology practice
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| Series E | $150M | Dec 2025 | |
| Series D | $550M | Sep 2025 | |
| Series F | $103M | Apr 2025 | |
| CCurevo Vaccine | Series B | $110M | Jan 2025 |
| Growth | — | Dec 2024 | |
| RRemodel Health | Unknown | $100M | Dec 2024 |
| SSynOx Therapeutics | Unknown | $92M | Oct 2024 |
| Growth | $23M | Jun 2024 | |
| Unknown | $150M | May 2024 | |
| RRemodel Health | Unknown | $100M | Jan 2024 |
| Series F | $300M | Dec 2023 | |
| Unknown | $315M | Oct 2023 | |
| Series C | $166M | May 2023 | |
| Unknown | $315M | Jan 2023 | |
| Series C | $166M | Jan 2023 | |
| Unknown | $60M | Jan 2023 | |
| MMadrigal Pharmaceuticals | Unknown | $159M | Dec 2022 |
| Series F | $117M | Nov 2022 | |
| OOak Street Health | Unknown | $300M | Nov 2022 |
| Growth | $132M | Oct 2022 | |
| CCompete | Series A | $15M | Mar 2022 |
| CCurevo Vaccine | Series A | $60M | Jan 2022 |
| NNorthsea Therapeutics | Series C | $80M | Dec 2021 |
| Series D | $235M | Sep 2021 | |
| Series B | $67.4M | May 2021 |
Top Co-Investors
Last updated: 7 September 2026